nach oben

CardioVascular and Interventional Radiology

Erschienen in:

01.06.2013 | CIRSE Standards of Practice Guidelines

Standards of Practice in Transarterial Radioembolization

verfasst von: Andreas H. Mahnken, Carlo Spreafico, Geert Maleux, Thomas Helmberger, Tobias F. Jakobs

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Excerpt

Primary cancer to the liver is the second most frequent cause of cancer death worldwide. There are 750,000 new cases of liver cancer worldwide [1], and metastatic liver disease is the most common cause of cancer death. Only about 25 % of patients with primary or secondary liver cancer are eligible for surgery, with a roughly 50 % 5-year overall survival in metastatic colorectal cancer (CRC) and little more than 20 months’ median overall survival with systemic chemotherapy alone [2]. Thus, interventional techniques evolved as a first-line treatment in primary liver tumors and are increasingly used in metastatic liver disease. Radiation-based approaches are appealing because they are known to be cytocidal in sufficient doses and they are independent from chemical or other energy-based treatment techniques. Although delivery of >70 Gy is thought to be needed to achieve solid tumor destruction [3], the tolerance of normal liver tissue is approximately 30 Gy [4]. These conditions resulted in the idea of selective transarterial radiation delivery and triggered the development of various transarterial radiation-based therapies, with ⁹⁰Y microspheres being the current mainstay of radioembolization (RE). …

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Davies JM, Goldberg RM (2011) Treatment of metastatic colorectal cancer. Semin Oncol 38:552–560PubMedCrossRef

Dawson LA, McGinn CJ, Normolle D et al (2000) Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18:2210–2218PubMed

Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821PubMedCrossRef

Ariel IM, Pack GT (1966) The treatment of cancer metastases in the lung by means of radiating microspheres. Thoraxchir Vask Chir 14:286–307PubMed

Simon N, Siffert R, Baron MG et al (1968) Preoperative irradiation of osteogenic sarcoma with intra-arterially injected yttrium-90 microspheres. Case report. Cancer 21:453–455

Blanchard RJ, LaFave JW, Kim YS (1965) Treatment of patients with advanced cancer using Y-90 microspheres. Cancer 18:375–380PubMedCrossRef

Mantravadi RV, Spigos DG, Tan WS et al (1982) Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology 142:783–786PubMed

Wollner I, Knutsen C, Smith P et al (1988) Effects of hepatic arterial yttrium 90 glass microspheres in dogs. Cancer 61:1336–1344PubMedCrossRef

10.

Shepherd FA, Rotstein LE, Houle S et al (1992) A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 70:2250–2254PubMedCrossRef

11.

Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 14:S199–S202PubMedCrossRef

12.

Van den Eynde M, Flamen P, El Nakadi I et al (2008) Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med 33:697–699PubMedCrossRef

13.

Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13–23PubMedCrossRef

14.

Iñarrairaegui M, Thurston KG, Bilbao JI et al (2010) Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 21:1205–1212PubMedCrossRef

15.

Stacul F, van der Molen AJ, Reimer P, Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) et al (2011) Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 21:2527–2541PubMedCrossRef

16.

Bush WH Jr (1999) Treatment of acute contrast reactions. In: Bush WH Jr, Krecke KN, King BF Jr et al (eds) Radiology Life Support. Oxford University Press, New York, pp 31–51

17.

Liu DM, Salem R, Bui JT et al (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16:911–935PubMedCrossRef

18.

Wright CL, Werner JD, Tran JM et al (2012) Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Interv Radiol 23:669–674PubMedCrossRef

19.

Ahmadzadehfar H, Sabet A, Biermann K et al (2010) The significance of ^99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for ⁹⁰Y-microsphere selective internal radiation treatment. J Nucl Med 51:1206–1212PubMedCrossRef

20.

Seidensticker R, Seidensticker M, Damm R et al (2012) Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol 35:1109–1118PubMedCrossRef

21.

Salem R, Lewandowski RJ, Gates VL, Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology et al (2011) Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 22:265–278PubMedCrossRef

22.

Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60PubMedCrossRef

23.

Gulec SA, Suthar RR, Barot TC, Pennington K (2011) The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing ⁹⁰Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging 38:1289–1295PubMedCrossRef

24.

Vente MA, Wondergem M, van der Tweel I et al (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19:951–959PubMedCrossRef

25.

Salem R, Lewandowski RJ, Mulcahy MF et al (2010) Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52–64PubMedCrossRef

26.

Sangro B, Carpanese L, Cianni R, European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY) et al (2011) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54:868–878PubMedCrossRef

27.

Hilgard P, Hamami M, Fouly AE et al (2010) Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52:1741–1749PubMedCrossRef

28.

Kulik LM, Carr BI, Mulcahy MF et al (2008) Safety and efficacy of ⁹⁰Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81PubMedCrossRef

29.

Lance C, McLennan G, Obuchowski N et al (2011) Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 22:1697–1705PubMedCrossRef

30.

D’Avola D, Lñarrairaegui M, Bilbao JI et al (2009) A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology 56:1683–1688PubMed

31.

Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507PubMedCrossRef

32.

Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711–1720PubMedCrossRef

33.

Van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78–85PubMedCrossRef

34.

Hendlisz A, Van den Eynde M, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694PubMedCrossRef

35.

Hong K, McBride JD, Georgiades CS et al (2009) Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 20:360–367PubMedCrossRef

36.

Riaz A, Lewandowski RJ, Kulik LM et al (2009) Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 20:1121–1130PubMedCrossRef

37.

Salem R, Parikh P, Atassi B et al (2008) Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 31:431–438PubMedCrossRef

38.

Murthy R, Brown DB, Salem R et al (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18:553–561PubMedCrossRef

39.

Kennedy AS, McNeillie P, Dezarn WA et al (2009) Treatment parameters and outcome in 680 treatments of internal radiation with resin (90)Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74:1494–1500PubMedCrossRef

40.

Kennedy AS, Coldwell D, Nutting C et al (2006) Resin ⁹⁰Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65:412–425PubMedCrossRef

41.

Stubbs RS, O’Brien I, Correia MM (2006) Selective internal radiation therapy with ⁹⁰Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 76:696–703PubMedCrossRef

42.

Sato KT, Lewandowski RJ, Mulcahy MF et al (2008) Unresectable chemorefractory liver metastases: radioembolization with ⁹⁰Y microspheres—safety, efficacy, and survival. Radiology 247:507–515PubMedCrossRef

43.

Mulcahy MF, Lewandowski RJ, Ibrahim SM et al (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115:1849–1858PubMedCrossRef

44.

Cosimelli M, Golfieri R, Cagol PP, Italian Society of Locoregional Therapies in Oncology (SITILO) et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324–331PubMedCrossRef

45.

Evans KA, Richardson MG, Pavlakis N et al (2010) Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. J Vasc Interv Radiol 21:1521–1526PubMedCrossRef

46.

Chua TC, Bester L, Saxena A, Morris DL (2011) Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 137:865–873PubMedCrossRef

47.

Rhee TK, Lewandowski RJ, Liu DM et al (2008) ⁹⁰Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247:1029–1035PubMedCrossRef

48.

Kennedy AS, Dezarn WA, McNeillie P et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin ⁹⁰Y-microspheres: early results in 148 patients. Am J Clin Oncol 31:271–279PubMedCrossRef

49.

King J, Quinn R, Glenn DM et al (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113:921–929PubMedCrossRef

50.

Saxena A, Chua TC, Bester L et al (2010) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251:910–916PubMedCrossRef

51.

Cao CQ, Yan TD, Bester L et al (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97:537–543PubMedCrossRef

52.

Paprottka PM, Hoffmann RT, Haug A et al (2012) Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 35:334–342PubMedCrossRef

53.

Jakobs TF, Hoffmann RT, Fischer T et al (2008) Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 19:683–690PubMedCrossRef

54.

Coldwell DM, Kennedy AS, Nutting CW (2007) Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 69:800–804PubMedCrossRef

55.

Bangash AK, Atassi B, Kaklamani V et al (2007) ⁹⁰Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 18:621–628PubMedCrossRef

56.

Gonsalves CF, Eschelman DJ, Sullivan KL et al (2011) Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol 196:468–473PubMedCrossRef

Titel: Standards of Practice in Transarterial Radioembolization
verfasst von: Andreas H. Mahnken
Carlo Spreafico
Geert Maleux
Thomas Helmberger
Tobias F. Jakobs
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 3/2013
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-013-0600-8

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Standards of Practice in Transarterial Radioembolization

Excerpt

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Radiologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Percutaneous CT-Guided Biopsy of C3 Vertebral Body: Modified Approach for an Old Procedure

Iliac Artery Stent Placement Relieves Claudication in Patients with Iliac and Superficial Femoral Artery Lesions

Percutaneous Intraductal Radiofrequency Ablation is a Safe Treatment for Malignant Biliary Obstruction: Feasibility and Early Results

Percutaneous Cryotherapy of Vascular Malformation: Initial Experience

Inferior Pancreaticoduodenal Artery Aneurysms Associated with Occlusive Lesions of the Celiac Axis: Diagnosis, Treatment Options, Outcomes, and Review of the Literature

Successful Recanalization of Acute Superior Mesenteric Artery Thromboembolic Occlusion by a Combination of Intraarterial Thrombolysis and Mechanical Thrombectomy with a Carotid Filter

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Radiologie